ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record

Rhea-AI Summary

ImmunoPrecise Antibodies Ltd. (IPA) announced the appointment of LifeSci Advisors as its investor relations agent. President and CEO Jennifer Bath expressed optimism about this partnership, emphasizing the importance of communication as the company evolves. LifeSci Advisors boasts a global presence and extensive client base, providing comprehensive solutions for investor outreach and visibility. IPA focuses on therapeutic antibody discovery and aims to innovate traditional product development models while enhancing client engagement.

Positive

• Partnership with LifeSci Advisors aims to enhance investor relations and visibility.
• LifeSci Advisors has a strong track record with over 500 clients globally.

Negative

• None.

IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it has selected and retained LifeSci Advisors as investor relations agent of record.

Jennifer Bath, President and CEO of ImmunoPrecise Antibodies commented, “We are pleased to partner with LifeSci Advisors for our investor relations advisory needs during this important stage of our Company’s evolution. With over 500 clients under contract globally, we look forward to continuing our discovery and development of proprietary novel antibodies while providing CRO services to 70% of the top 20 pharma.”

LifeSci Advisors (“LSA”), with over 250 employees and a local presence that spans, New York, Chicago, Boston, London, Geneva, Paris, and Tel-Aviv, provides life science companies comprehensive solutions to communications and investor outreach. Taking a partner approach, LSA increases client visibility within the investment community and educates investors on opportunities with its clients through non-deal roadshow planning and execution, KOL Events/R&D Days, and corporate communications.

About ImmunoPrecise Antibodies Ltd.

IPA is an innovation-driven, technology platform company that supports its pharmaceutical and biotechnology company partners in their quest to discover and develop novel, therapeutic antibodies against all classes of disease targets. The Company aims to transform the conventional, multi-vendor, product development model by bringing innovative and high-throughput, data-driven technologies to its partners, incorporating the advantages of diverse antibody repertoires with the Company’s therapeutic antibody discovery suite of technologies, to exploit antibodies of broad epitope coverage, multiple antibody formats, valency and size, and to discover antibodies against multiple/rare epitopes. For further information, visit www.immunoprecise.com or contact solutions@immunoprecise.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005374/en/

FAQ

What is the recent announcement by ImmunoPrecise Antibodies (IPA)?

ImmunoPrecise Antibodies announced the appointment of LifeSci Advisors as its investor relations agent.

Who is LifeSci Advisors in relation to ImmunoPrecise Antibodies (IPA)?

LifeSci Advisors is the newly appointed investor relations agent for ImmunoPrecise Antibodies.

What does the partnership with LifeSci Advisors mean for IPA?

The partnership aims to enhance IPA's investor relations and visibility in the investment community.

What services will LifeSci Advisors provide to ImmunoPrecise Antibodies (IPA)?

LifeSci Advisors will provide solutions for communications and investor outreach.

What are the goals of ImmunoPrecise Antibodies (IPA) in their business model?

IPA aims to innovate therapeutic antibody discovery and support pharmaceutical partners in developing novel antibodies.